CPHRF
Cipher Pharmaceuticals Inc.
OTC Markets OTCQXUSDEQUITY
Healthcare
DELAYED
Last price
10.37
▲ 0.09 (0.88%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
10.32
Prev close
10.28
Day high
10.32
Day low
10.32
Volume
5
Market cap
$263.55M
P/E (TTM)
9.26
52W range
8.92 – 15.00
Day trading desk
Gap from prior close
+0.39%
Prior close 10.28
VWAP
—
—
Relative volume
0.00×
Quiet session
Session range
0.48%
10.32 – 10.37
Position in range
100%
Near session high
ATR (14D)
0.45
4.35% of price
Prior day high
10.32
PDH
Prior day low
10.26
PDL
Bid / ask spread
—
Quote not published
Session volume
—
Avg 4.69K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+1.77%
+3.1%
1M
-10.76%
-14.5%
3M
-15.35%
-18.4%
6M
-6.24%
-17.3%
YTD
-5.56%
-17.8%
1Y
-1.52%
-21.5%
3Y
+286.94%
+212.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CPHRF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
10.76M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 24, 26 | Deeth, Douglas Norman Director of Issuer |
EXERCISE | 2.50K | $28.44K | Direct |
| Jun 24, 26 | Deeth, Douglas Norman Director of Issuer |
EXERCISE | 1.15K | $13.17K | Direct |
| Jun 24, 26 | Mull (Craig James) 10% Security Holder of Issuer |
EXERCISE | 2.50K | $28.44K | Direct |
| Jun 24, 26 | Walinski (Hubert) Director of Issuer |
EXERCISE | 2.50K | $28.44K | Direct |
| Jun 24, 26 | Walinski (Hubert) Director of Issuer |
EXERCISE | 1.15K | $13.17K | Direct |
| Mar 24, 26 | Mull (Craig James) 10% Security Holder of Issuer |
EXERCISE | 83.90K | $1.03M | Direct |
| Mar 20, 26 | Jacobs (Bryan) Senior Officer of Issuer |
EXERCISE | 7.50K | $12.62K | Direct |
| Mar 20, 26 | Jacobs (Bryan) Senior Officer of Issuer |
SELL | 7.50K | $91.27K | Direct |
| Mar 18, 26 | Jacobs (Bryan) Senior Officer of Issuer |
EXERCISE | 4.18K | $49.31K | Direct |
| Mar 18, 26 | Jacobs (Bryan) Senior Officer of Issuer |
EXERCISE | 1.83K | $22.83K | Direct |
| Mar 18, 26 | Jacobs (Bryan) Senior Officer of Issuer |
EXERCISE | 7.50K | $12.62K | Direct |
| Mar 18, 26 | Jacobs (Bryan) Senior Officer of Issuer |
SELL | 7.50K | $94.38K | Direct |
| Dec 31, 25 | Cipher Pharmaceuticals, Inc. Issuer |
BUY | 95.45K | $1.01M | Direct |
| Dec 31, 25 | Cipher Pharmaceuticals, Inc. Issuer |
BUY | 95.45K | $1.01M | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
Cipher Pharmaceuticals, Inc. |
Issuer | 95.45K | Redemption, retraction, cancelation, repurchase |
Deeth, Douglas Norman |
Director of Issuer | 3.84K | Exercise of rights |
Jacobs (Bryan) |
Senior Officer of Issuer | 16.59K | Exercise of options |
Mull (Craig James) |
10% Security Holder of Issuer | 989.95K | Exercise of rights |
Walinski (Hubert) |
Director of Issuer | 3.84K | Exercise of rights |
Wolkin (Harold Morton) |
Director of Issuer | 377.98K | Exercise of rights |
Fundamentals
Market cap$263.55M
Enterprise value$254.81M
Revenue (TTM)$49.62M
Gross profit$40.40M
EBITDA$26.48M
Net income$28.99M
EPS (TTM)$1.12
Free cash flow$19.21M
Total cash$9.11M
Total debt$367.00K
Book value / share$5.40
Shares outstanding25.42M
Float14.84M
Short % of float—
Dividend yield—
Beta (5Y)0.46
Valuation & profitability ratios
Trailing P/E9.26
Forward P/E20.74
PEG ratio—
Price / sales—
Price / book1.92
EV / revenue5.14
EV / EBITDA9.62
Gross margin81.40%
Operating margin39.23%
Profit margin58.42%
Return on equity23.50%
Return on assets7.97%
Debt / equity0.27
Current ratio1.59
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $50.45M | $33.36M | $21.16M | $20.68M | +51.2% |
| Operating revenue | $50.45M | $33.36M | $21.16M | $20.68M | +51.2% |
| Cost of revenue | $10.03M | $9.26M | $4.07M | $3.99M | +8.3% |
| Gross profit | $40.42M | $24.10M | $17.09M | $16.68M | +67.7% |
| Research & development | $21.00K | $0 | $139.00K | $98.00K | — |
| Selling, general & admin | $16.30M | $12.24M | $5.42M | $4.55M | +33.2% |
| Total operating expense | $23.56M | $16.25M | $6.79M | $5.63M | +44.9% |
| Operating income | $16.86M | $7.85M | $10.30M | $11.05M | +114.9% |
| Net interest income | -$1.17M | $330.00K | $1.87M | $464.00K | -453.0% |
| Pre-tax income | $17.16M | $2.96M | $12.68M | $11.48M | +480.8% |
| Tax provision | -$10.17M | -$8.59M | -$7.70M | -$15.16M | -18.3% |
| Net income | $27.33M | $11.54M | $20.38M | $26.64M | +136.7% |
| Net income to common | $27.33M | $11.54M | $20.38M | $26.64M | +136.7% |
| Basic EPS | 1.07 | 0.47 | 0.82 | 1.05 | +127.7% |
| Diluted EPS | 1.05 | 0.46 | 0.80 | 1.03 | +128.3% |
| EBIT | $16.86M | $7.85M | $10.30M | $11.05M | +114.9% |
| EBITDA | $24.10M | $11.87M | $11.53M | $12.04M | +103.1% |
| Basic shares | 25.48M | 24.56M | 24.86M | 25.38M | +3.7% |
| Diluted shares | 25.99M | 25.10M | 25.48M | 25.80M | +3.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $7.49M | $17.84M | $39.83M | $28.84M | -58.0% |
| Cash & short-term investments | $7.49M | $17.84M | $39.83M | $28.84M | -58.0% |
| Accounts receivable | $11.21M | $13.86M | $5.09M | $6.80M | -19.1% |
| Inventory | $8.19M | $5.79M | $2.98M | $2.15M | +41.4% |
| Total current assets | $28.05M | $38.48M | $48.27M | $38.16M | -27.1% |
| Property, plant & equipment | $569.00K | $680.00K | $402.00K | $481.00K | -16.3% |
| Goodwill & intangibles | $89.46M | $96.20M | $17.47M | $18.46M | -7.0% |
| Total assets | $156.50M | $162.51M | $86.03M | $73.78M | -3.7% |
| Total current liabilities | $25.04M | $19.87M | $5.25M | $9.37M | +26.0% |
| Long-term debt | $5.00M | $40.00M | — | — | -87.5% |
| Total debt | $5.50M | $40.58M | $353.00K | $428.00K | -86.4% |
| Total liabilities | $30.26M | $60.17M | $5.51M | $9.70M | -49.7% |
| Retained earnings | $100.11M | $77.65M | $66.27M | $50.52M | +28.9% |
| Shareholder equity | $126.24M | $102.34M | $80.52M | $64.08M | +23.4% |
| Working capital | $3.00M | $18.61M | $43.02M | $28.79M | -83.9% |
| Net tangible assets | $36.78M | $6.14M | $63.05M | $45.62M | +498.9% |
| Shares issued | 25.28M | 25.60M | 23.99M | 25.06M | -1.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $27.33M | $11.54M | $20.38M | $26.64M | +136.7% |
| Depreciation & amortisation | $7.23M | $4.02M | $1.23M | $989.00K | +80.0% |
| Stock-based compensation | $1.74M | $1.07M | $1.19M | $403.00K | +62.1% |
| Change in working capital | $5.23M | $8.95M | -$3.28M | -$3.03M | -41.6% |
| Operating cash flow | $29.73M | $19.55M | $16.00M | $10.72M | +52.1% |
| Capital expenditure | -$201.00K | -$44.00K | -$21.00K | -$81.00K | -356.8% |
| Investing cash flow | -$71.00K | -$80.04M | -$144.00K | -$81.00K | +99.9% |
| Share buybacks | -$5.38M | -$176.00K | -$5.56M | -$1.99M | -2,957.4% |
| Financing cash flow | -$40.47M | $39.30M | -$5.24M | -$1.91M | -203.0% |
| Free cash flow | $29.52M | $19.50M | $15.98M | $10.64M | +51.4% |
| End cash position | $7.49M | $17.84M | $39.83M | $28.84M | -58.0% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $12.51M | $12.22M | $12.83M | $13.38M | $12.02M | — | +2.3% |
| Operating revenue | $12.51M | $12.22M | $12.83M | $13.38M | $12.02M | — | +2.3% |
| Cost of revenue | $2.21M | $2.30M | $2.35M | $2.50M | $2.88M | — | -4.2% |
| Gross profit | $10.30M | $9.91M | $10.48M | $10.88M | $9.14M | — | +3.9% |
| Research & development | $0 | $0 | $0 | $0 | $21.00K | — | — |
| Selling, general & admin | $2.90M | $3.68M | $3.71M | $4.08M | $4.82M | — | -21.4% |
| Total operating expense | $4.70M | $5.49M | $5.51M | $5.89M | $6.67M | — | -14.3% |
| Operating income | $5.59M | $4.43M | $4.97M | $4.99M | $2.47M | — | +26.4% |
| Net interest income | -$51.00K | -$109.00K | -$241.00K | -$345.00K | -$470.00K | — | +53.2% |
| Pre-tax income | $4.95M | $4.61M | $4.26M | $6.41M | $1.89M | — | +7.3% |
| Tax provision | -$1.21M | -$8.70M | -$1.24M | $512.00K | -$737.00K | — | +86.0% |
| Net income | $6.16M | $13.31M | $5.50M | $5.89M | $2.62M | — | -53.7% |
| Net income to common | $6.16M | $13.31M | $5.50M | $5.89M | $2.62M | — | -53.7% |
| Basic EPS | 0.24 | — | 0.22 | 0.23 | 0.10 | 0.13 | — |
| Diluted EPS | 0.24 | — | 0.21 | 0.22 | 0.10 | 0.13 | — |
| EBIT | $5.00M | $4.43M | $4.97M | $4.99M | $2.36M | — | +13.0% |
| EBITDA | $6.81M | $6.23M | $6.77M | $6.80M | $4.18M | — | +9.2% |
| Basic shares | 25.28M | — | 25.37M | 25.87M | 25.61M | 25.72M | — |
| Diluted shares | 25.80M | — | 25.95M | 26.51M | 26.20M | 25.72M | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $6.41M | $7.49M | $8.42M | $11.34M | $22.00M | — | -14.5% |
| Cash & short-term investments | $6.41M | $7.49M | $8.42M | $11.34M | $22.00M | — | -14.5% |
| Accounts receivable | $9.75M | $11.21M | $10.13M | $11.87M | $11.77M | — | -13.0% |
| Inventory | $8.20M | $8.19M | $6.71M | $5.58M | $5.54M | — | +0.1% |
| Total current assets | $25.50M | $28.05M | $26.66M | $30.55M | $40.15M | — | -9.1% |
| Property, plant & equipment | $478.00K | $569.00K | $453.00K | $522.00K | $602.00K | — | -16.0% |
| Goodwill & intangibles | $88.29M | $89.46M | $91.09M | $92.73M | $94.46M | — | -1.3% |
| Total assets | $153.28M | $156.50M | $147.50M | $152.39M | $163.07M | — | -2.1% |
| Total current liabilities | $20.37M | $25.04M | $20.43M | $17.76M | $17.59M | — | -18.7% |
| Long-term debt | — | $5.00M | $13.00M | $25.00M | $40.00M | $40.00M | — |
| Total debt | $428.00K | $5.50M | $13.39M | $25.45M | $40.51M | — | -92.2% |
| Total liabilities | $20.53M | $30.26M | $33.57M | $42.96M | $57.83M | — | -32.1% |
| Retained earnings | $106.28M | $100.11M | $88.30M | $84.25M | $80.28M | — | +6.2% |
| Shareholder equity | $132.75M | $126.24M | $113.94M | $109.44M | $105.24M | — | +5.2% |
| Working capital | $5.13M | $3.00M | $6.23M | $12.79M | $22.56M | — | +70.7% |
| Net tangible assets | $44.45M | $36.78M | $22.84M | $16.70M | $10.78M | — | +20.9% |
| Shares issued | 25.39M | 25.28M | 25.37M | 25.39M | 25.62M | — | +0.4% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $6.16M | $13.31M | $5.50M | $5.89M | $2.62M | — | -53.7% |
| Depreciation & amortisation | $1.81M | $1.81M | $1.80M | $1.81M | $1.82M | — | +0.1% |
| Stock-based compensation | $304.00K | $525.00K | $533.00K | $436.00K | $244.00K | — | -42.1% |
| Change in working capital | -$3.17M | $2.25M | $3.66M | -$914.00K | $230.00K | — | -240.9% |
| Operating cash flow | $4.52M | $8.73M | $10.76M | $6.02M | $4.22M | — | -48.2% |
| Capital expenditure | -$560.00K | -$118.00K | -$81.00K | — | -$2.00K | -$7.00K | -374.6% |
| Investing cash flow | -$492.00K | -$118.00K | $49.00K | $0 | -$2.00K | — | -316.9% |
| Share buybacks | — | -$1.66M | -$1.58M | -$2.14M | $0 | $0 | — |
| Financing cash flow | -$5.04M | -$9.62M | -$13.60M | -$17.21M | -$45.00K | — | +47.6% |
| Free cash flow | $3.96M | $8.61M | $10.68M | $6.02M | $4.22M | — | -54.0% |
| End cash position | $6.41M | $7.49M | $8.42M | $11.34M | $22.00M | — | -14.5% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.19 | 0.15 | -21.0% |
| Dec 2025 | 0.16 | 0.51 | +229.0% |
| Sep 2025 | 0.13 | 0.21 | +68.0% |
| Jun 2025 | 0.16 | 0.22 | +37.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.19 | 2 | $18.31M | -0.5% |
| Next quarter | 0.23 | 2 | $18.50M | +11.2% |
| Current year | 0.81 | 4 | $70.88M | +3.1% |
| Next year | 0.89 | 3 | $82.69M | +16.7% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusBUY
Strong buy / Buy1 / 2
Hold1
Sell / Strong sell0 / 0
Held by insiders42.35%
Held by institutions1.30%
Institutions holding6
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
10.73
-3.32% from price
SMA 20
11.35
-8.65% from price
SMA 50
11.56
-10.26% from price
SMA 100
12.26
-15.42% from price
SMA 200
11.54
-10.11% from price
EMA 12
10.78
-3.80% from price
EMA 26
11.22
-7.55% from price
EMA 50
11.54
-10.10% from price
RSI (14)
35.2
Neutral
MACD (12,26,9)
-0.44
Hist -0.16
ATR (14)
0.45
4.35% of price
Realised vol 30D
70.1%
Annualised
Bollinger upper
13.30
20, 2σ
Bollinger lower
9.40
20, 2σ
50 / 200 cross
Golden
11.56 vs 11.54
Trend bias
Below 200
-10.11%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.25
Less volatile than market
Correlation to SPY
0.08
Largely independent
Realised vol 30D
70.1%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-29.7%
Peak to trough
Max drawdown 5Y
-55.4%
Peak to trough
ATR 14
0.45
4.35% of price
Beta (reported)
0.46
5Y monthly, from filing
Short interest
Shares short
10.49K
Prior 48.42K
Change vs prior
-78.3%
Shorts covering
% of float
—
—
% of shares out
0.04%
Against total outstanding
Days to cover
1.0
Liquid
Float
14.84M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 1, 23 | Stifel | UPGRADE | Hold | Speculative Buy |
Headlines
Cipher Pharmaceuticals Inc (CPHRF) (Q2 2026) Earnings Call Highlights: Epuris Growth and ...
GuruFocus.com · 11d ago
Cipher Pharmaceuticals Q2 Earnings Call Highlights
MarketBeat · 11d ago
Cipher Pharmaceuticals Reports Second Quarter 2026 Results
CNW Group · 12d ago
Cipher Pharmaceuticals Schedules Q2 2026 Earnings Release and Conference Call
CNW Group · 23d ago
Cipher Pharmaceuticals Inks LOI With pCPA to List Severe Acne Treatment Epuris
MT Newswires · 47d ago
Cipher Pharmaceuticals and the pan-Canadian Pharmaceutical Alliance (pCPA) Sign Letter of Intent for Public Drug Plan Coverage of Epuris®
CNW Group · 48d ago
Cipher Pharmaceuticals Announces Results of Annual General Meeting of Shareholders
CNW Group · 66d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.